Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Alzamend Neuro, Inc. (ALZN)
|
Add to portfolio |
|
|
|
| Price: |
$2.23
| | Metrics |
| OS: |
96.9
|
M
| |
-489
|
% ROE
|
| Market cap: |
$216
|
M
| |
|
|
|
Net cash:
|
$5.14
|
M
| |
$0.05
|
per share
|
|
EV:
|
$211
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($14.8)
|
M
| |
|
|
|
EBIT
|
($14.9)
|
M
| |
|
|
| EPS |
($0.15)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Apr-30-23 | Apr-30-22 | Apr-30-21 | Apr-30-20 | Apr-30-19 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 3.7 |
| Revenue growth | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 5.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | -1.3 |
| Gross margin | | | | | -35.4% |
| Research and development | 7.4 | 5.2 | 1.3 | 1.1 | |
| General and administrative | 7.4 | 7.1 | 3.6 | 3.4 | 1.3 |
| EBIT | -14.9 | -12.3 | -5.0 | -4.4 | -5.0 |
| EBIT margin | | | | | -135.4% |
| Pre-tax income | -14.9 | -12.4 | -5.0 | -4.4 | -4.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -14.9 | -12.4 | -5.0 | -4.4 | -4.9 |
| Net margin | | | | | -131.4% |
| |
| Diluted EPS | ($0.15) | ($0.14) | ($0.07) | ($0.06) | ($0.08) |
| Shares outstanding (diluted) | 97.5 | 89.1 | 72.7 | 71.3 | 58.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|